na-BYOO-me-tone 
Contraindicated in:
Use Cautiously in:
CV: HF, MI, STROKE, edema, hypertension, vasculitis.
Derm: DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS (DRESS), EXFOLIATIVE DERMATITIS, STEVENS-JOHNSON SYNDROME, TOXIC EPIDERMAL NECROLYSIS, increased sweating, photosensitivity, pruritus, rash.
EENT: abnormal vision, tinnitus.
GI: GI BLEEDING, abdominal pain, diarrhea, ↑ liver function tests, anorexia, constipation, dry mouth, dyspepsia, flatulence, gastritis, gastroenteritis, ↑ appetite, nausea, stomatitis, vomiting.
GU: albuminuria, azotemia, interstitial nephritis.
Hemat: prolonged bleeding time.
Metab: weight gain.
Neuro: agitation, anxiety, confusion, depression, dizziness, drowsiness, fatigue, headache, insomnia, malaise, paresthesia, tremor, weakness.
Resp: dyspnea, hypersensitivity pneumonitis.
Misc: HYPERSENSITIVITY REACTIONS (INCLUDING ANAPHYLAXIS AND ANGIOEDEMA).
Drug-Drug:
Therapeutic Classification: antirheumatics, nonopioid analgesics
Pharmacologic Classification: nonsteroidal anti-inflammatory drugs (NSAIDs)
Absorption: Nabumetone (a prodrug) is 80% absorbed after oral administration; 35% is rapidly converted to 6-methoxy-2-naphthylacetic acid (6-MNA), which is the active drug.
Distribution: Unknown.
Protein Binding: >99%.
Metabolism/Excretion: 6-MNA is metabolized by the liver to inactive compounds.
Half-life: 24 hr (↑ in severe renal impairment).
NDC Code*